Sangivamycin
Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2].
Product Specifications
CAS Number
18417-89-5
Product Name Alternative
NSC 65346; BA-90912
UNSPSC
12352005
Hazard Statement
H300
Target
Nucleoside Antimetabolite/Analog; PKC
Type
Natural Products
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sangivamycin.html
Concentration
10mM
Purity
97.68
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC=NC(N)=C3C(C(N)=O)=C2)O1
Molecular Formula
C12H15N5O5
Molecular Weight
309.28
Precautions
H300
References & Citations
[1]Loomis CR, Bell RM. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem. 1988;263 (4) :1682-1692.|[2]Lee SA, et al. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. J Biol Chem. 2007;282 (20) :15271-15283.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
S7958-51A-ML750 100 µL
Stanniocalcin-2, NT (Stanniocalcin 2, STC-2, Stanniocalcin-related Protein, STCRP, STC-related Protein) (MaxLight 750) discontinued
Sign In for Pricing
View Details RDR-VRK1-Hu-96Tests 96 Tests
Human Vaccinia Related Kinase 1 (VRK1) ELISA Kit
Sign In for Pricing
View Details 
orb1462576-01 20 µg
CD15 / FUT4 (Reed-Sternberg Cell Marker) Antibody - With BSA and Azide
Sign In for Pricing
View Details orb1462576-02 100 µg
CD15 / FUT4 (Reed-Sternberg Cell Marker) Antibody - With BSA and Azide
Sign In for Pricing
View Details 